Hormone replacement therapy and the prevention of postmenopausal osteoporosis

Przeglad Menopauzalny

Volumn 13, Issue 4, 2014, Pages 213-220

  Gambacciani, Marco ^a   Levancini, Marco ^a,b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Estrogen; Fracture; Menopause; Osteoporosis; Prevention

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; LOW DOSE ORAL CONTRACEPTIVE; RALOXIFENE; TAMOXIFEN; TIBOLONE;

BONE DENSITY; BONE TURNOVER; DRUG EFFICACY; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOARTHRITIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SPINE FRACTURE; VAGINA ATROPHY;

EID: 84924662346     PISSN: 16438876     EISSN: 22990038     Source Type: Journal    
DOI: 10.5114/pm.2014.44996     Document Type: Review

References (48)

1. Osteoporosis Prevention, Diagnosis and Therapy. NIH Consensus Statement 2000; 17: 1-45.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-1733.
3. Leslie WD, Morin SN. Osteoporosis epidemiology 2013: implications for diagnosis, risk assessment, and treatment. Curr Opin Rheumatol 2014; 26: 440-446.
4. Cummins SR, Melton LJ 3rd. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
5. Brincat M, Calleja-Agius J, Erel CT, et al; EMAS. EMAS position statement: Bone densitometry screening for osteoporosis. Maturitas 2011; 68: 98-101.
6. Gambacciani M, Spinetti A, de Simone L, et al. The relative contributions of menopause and aging to postmenopausal vertebral osteopenia. J Clin Endocrinol Metab 1993; 77: 1148-1151.
7. Gambacciani M, Ciaponi M. Postmenopausal osteoporosis management. Curr Opin Obstet Gynecol 2000; 12: 189-197.
8. Crandall CJ, Zheng Y, Crawford SL, et al. Presence of vasomotor symptoms is associated with lower bone mineral density: a longitudinal analysis. Menopause 2009; 16: 239-246.
9. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am 2011; 38: 489-501.
10. Genazzani AR, Gambacciani M, Schneider HP, et al.; International Menopause Society Expert Workshop. Postmenopausal osteoporosis: therapeutic options. Climateric 2005; 8: 99-109.
11. Reifenstein E, Albright F. The metabolic effects of steroid hormones in osteoporosis. J Clin Invest 1947; 26: 24-56.
12. Gambacciani M, Spinetti A, Taponeco F, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994; 83: 392-396.
13. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529-539.
14. Lindsay R, Hart CM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759-763.
15. Ribot C, Tremollieres F, Pouilles JM. Cyclic Estraderm TTS 50 plus oral progestogen in the prevention of postmenopausal bone loss over 24 months. In: Christiansen C, Overgaard K (eds.). Osteoporosis 1990. Vol 2. Osteopress ApS, Copenhagen 1990; pp. 1979-1984.
16. Effects of hormone replacement therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276: 1389-1396.
17. Lindsay R, Bush TL, Grady D, et al. Therapeutic controversy: estrogen replacement in menopause. J Clin Endocrinol Metab 1996; 81: 3829-3838.
18. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/ Estrogen Study Group. J Clin Endocrinol Metab 2000; 85: 720-726.
19. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of non-vertebral fractures. A meta-analysis of randomized trials. JAMA 2001; 285: 2891-2897.
20. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone density. The Rancho Bernado Study. JAMA 1997; 277: 543-547.
21. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
22. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-3253.
23. Beral V; Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
24. de Villiers TJ, Pines A, Panay N, et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013; 16: 316-337.
25. de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013; 16: 203-204.
26. Yates J, Barrett-Connor E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004; 103: 440-446.
27. Gambacciani M, Monteleone P, Genazzani AR. Low-dose hormone replacement therapy: effects on bone. Climacteric 2002; 5: 135-139.
28. Gambacciani M, Ciaponi M, Cappagli B, et al. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gynecol Endocrinol 2004; 18: 9-16.
29. Lindsay R, Gallagher C, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287: 2668-2676.
30. Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008; 59: 2-6.
31. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998; 41: 1343-1355.
32. Claassen H, Hornberger F, Scholz-Ahrens K, et al. The effect of estrogens and dietary calcium deficiency on the extracellular matrix of articular cartilage in Gottingen miniature pigs. Ann Anat 2002; 184: 141-148.
33. Felson DT, Nevitt MC. The effects of estrogen on osteoarthritis. Curr Opin Rheumatol 1998; 10: 269-272.
34. Gruber HE, Yamaguchi D, Ingram J, et al. Expression and localization of the estrogen receptor-beta in annulus cells of the human intervertebral disc and the mitogenic effect of 17-beta-estradiol in vitro. BMC Musculoskelet Disord 2002; 3: 4.
35. Gambacciani M, Pepe A, Cappagli B, et al. The relative contributions of menopause and aging to postmenopausal reduction in intervertebral disk height. Climacteric 2007; 10: 298-305.
36. Muscat Baron Y, Brincat MP, Galea R, et al. Low intervertebral disc height in postmenopausal women with osteoporotic vertebral fractures compared to hormone-treated and untreated postmenopausal women and premenopausal women without fractures. Climacteric 2007; 10: 314-319.
37. Christgau S, Tankó LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and ovariectomized rats by estrogen and a selective estrogen receptor modulator (SERM). Menopause 2004; 11: 508-518.
38. Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001; 86: 4717-4726.
39. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697-708.
40. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451-1467.
41. Grady D, Ettinger B, Moscarelli E, et al.; Multiple Outcomes of Raloxifene Evaluation Investigators. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004; 104: 837-844.
42. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
43. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-and active-controlled study. J Bone Miner Res 2008; 23: 525-535.
44. Genant HK. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Menopause Int 2011; 17: 44-49.
45. Lobo RA, Pinkerton JV, Gass MLS, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile. Fertil Steril 2009; 92: 1025-1038.
46. Gambacciani M, Ciaponi M, Genazzani AR. The HRT misuse and osteoporosis epidemic: a possible future scenario. Climacteric 2007; 10: 273-275.
47. Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011; 18: 1172-1177.
48. Gambacciani M. HRT misuse and the osteoporosis epidemic. Climacteric 2012; 15: 10-11.